A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia

Trial Profile

A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2016

At a glance

  • Drugs Conivaptan (Primary)
  • Indications Hyponatraemia
  • Focus Therapeutic Use
  • Sponsors Cumberland Pharmaceuticals
  • Most Recent Events

    • 10 Feb 2016 Results published in the Cumberland Pharmaceuticals Media Release.
    • 01 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top